Literature DB >> 23298252

Association between inotrope treatment and 90-day mortality in patients with septic shock.

E Wilkman1, K-M Kaukonen, V Pettilä, A Kuitunen, M Varpula.   

Abstract

BACKGROUND: Administration of inotropes in septic patients with low cardiac output or low central/mixed venous saturation is recommended in current guidelines. However, the impact of inotrope use on the outcome of these patients is controversial. We aimed to analyse the association of inotrope treatment with 90-day mortality.
METHODS: Data from 420 consecutive patients with septic shock were retrospectively collected from the intensive care unit (ICU) data management system. Factors associated with inotrope treatment were assessed. The association of 90-day mortality with inotrope treatment was first analysed using logistic regression analysis, and second including propensity score based on observed variables for selection to inotrope treatment. A subgroup analysis was performed for the 252 patients with pulmonary artery catheter.
RESULTS: One hundred eighty-six (44.3%) patients received inotrope treatment during the first 24 h in ICU. Of those, 168 (90.3%) received dobutamine, 29 (15.6%) levosimendan, and 23 (12.4%) epinephrine. Blood lactate (P < 0.001), central venous pressure, (P < 0.001), and norepinephrine dose (P = 0.03) were independently associated with inotrope treatment. Patients with inotrope treatment had a higher 90-day mortality (42.5% vs. 23.9%, P < 0.001). Age (P < 0.001), Acute Physiology and Chronic Health Evaluation II score (P < 0.001), and inotrope treatment (P = 0.003) were independently associated with 90-day mortality also after adjustment with propensity score.
CONCLUSION: The use of inotrope treatment in septic shock was associated with increased 90-day mortality without and after adjustment with propensity to receive inotrope. To differentiate between non-observed biases of severity of septic shock and an unfavourable effect of inotropes, prospective studies are needed.
© 2013 The Acta Anaesthesiologica Scandinavica Foundation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23298252     DOI: 10.1111/aas.12056

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  27 in total

1.  Frugal innovation for critical care.

Authors:  Armand Mekontso Dessap
Journal:  Intensive Care Med       Date:  2018-10-04       Impact factor: 17.440

2.  Preoperative risk factors of hemodynamic instability during laparoscopic adrenalectomy for pheochromocytoma.

Authors:  Sébastien Gaujoux; Stéphane Bonnet; Claude Lentschener; Jean-Marc Thillois; Denis Duboc; Jérôme Bertherat; Charles Marc Samama; Bertrand Dousset
Journal:  Surg Endosc       Date:  2015-12-18       Impact factor: 4.584

3.  Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.

Authors:  Christian Radke; Dagmar Horn; Christian Lanckohr; Björn Ellger; Michaela Meyer; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

Review 4.  [Catecholamines: pro and contra].

Authors:  R Riessen; O Tschritter; U Janssens; M Haap
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-03-25       Impact factor: 0.840

Review 5.  Vasoactive agents for the treatment of sepsis.

Authors:  Zhongheng Zhang; Kun Chen
Journal:  Ann Transl Med       Date:  2016-09

Review 6.  Pathophysiology of sepsis-induced cardiomyopathy.

Authors:  Steven M Hollenberg; Mervyn Singer
Journal:  Nat Rev Cardiol       Date:  2021-01-20       Impact factor: 32.419

7.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.

Authors:  Laura Evans; Andrew Rhodes; Waleed Alhazzani; Massimo Antonelli; Craig M Coopersmith; Craig French; Flávia R Machado; Lauralyn Mcintyre; Marlies Ostermann; Hallie C Prescott; Christa Schorr; Steven Simpson; W Joost Wiersinga; Fayez Alshamsi; Derek C Angus; Yaseen Arabi; Luciano Azevedo; Richard Beale; Gregory Beilman; Emilie Belley-Cote; Lisa Burry; Maurizio Cecconi; John Centofanti; Angel Coz Yataco; Jan De Waele; R Phillip Dellinger; Kent Doi; Bin Du; Elisa Estenssoro; Ricard Ferrer; Charles Gomersall; Carol Hodgson; Morten Hylander Møller; Theodore Iwashyna; Shevin Jacob; Ruth Kleinpell; Michael Klompas; Younsuck Koh; Anand Kumar; Arthur Kwizera; Suzana Lobo; Henry Masur; Steven McGloughlin; Sangeeta Mehta; Yatin Mehta; Mervyn Mer; Mark Nunnally; Simon Oczkowski; Tiffany Osborn; Elizabeth Papathanassoglou; Anders Perner; Michael Puskarich; Jason Roberts; William Schweickert; Maureen Seckel; Jonathan Sevransky; Charles L Sprung; Tobias Welte; Janice Zimmerman; Mitchell Levy
Journal:  Intensive Care Med       Date:  2021-10-02       Impact factor: 17.440

8.  A case study of likely wild-type cardiac transthyretin amyloidosis causing rapid deterioration.

Authors:  Thomas Davies; Aarash Saleh; Gerry Coghlan; Carol Whelan; Banwari Agarwal
Journal:  J Intensive Care Soc       Date:  2016-11-29

Review 9.  A review of sepsis-induced cardiomyopathy.

Authors:  Ryota Sato; Michitaka Nasu
Journal:  J Intensive Care       Date:  2015-11-11

10.  In-hospital mortality following treatment with red blood cell transfusion or inotropic therapy during early goal-directed therapy for septic shock: a retrospective propensity-adjusted analysis.

Authors:  Dustin G Mark; John W Morehouse; Yun-Yi Hung; Mamata V Kene; Andrew R Elms; Vincent Liu; Dustin W Ballard; David R Vinson
Journal:  Crit Care       Date:  2014-09-12       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.